HOLLISTON, Mass., Oct. 13, 2016 -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its third quarter 2016 after market trading hours on Thursday, October 27, 2016. A conference call to discuss the company's third quarter 2016 financial results and its operations is scheduled for that same date at 4:30 PM ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
Participating in the call will be Jeffrey A. Duchemin, President and Chief Executive Officer; and Robert Gagnon, Chief Financial Officer of Harvard Bioscience. Investors can access the live conference call by dialing the following phone numbers: toll-free 1-800-708-4540, or international: 1-847-619-6397, and referencing the conference ID# 43551089.
The conference will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the webcast at: http://investor.harvardbioscience.com/ and click on the Earnings Call icon. Financial information presented on the call, including the earnings release, will also be available on the investor relations section of the website.
If you are unable to listen to the live conference call, the webcast will be available on the Company's website through November 3, 2016.
To add this meeting to your calendar visit: http://investor.harvardbioscience.com/ and click “remind me”.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, GE Healthcare, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.
CONTACTS: Jeffrey A. Duchemin CEO and President Robert E. Gagnon CFO Corey Manchester Director, Finance and Investor Relations Tel: 508 893 8999


Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
First Western Ship Transits Strait of Hormuz Since Iran War Began
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Britain Courts Anthropic Amid US Defense Department Dispute
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 



